Updated:
CellCarta Inc.
CellCarta Inc. is based in Montreal; the profile covers headquarters, registration, AUM band and key contacts for private-markets fundraising.
Overview
Discover CellCarta's precision medicine testing services. Explore immunology, histopathology, proteomics, genomics, and digital pathology.
General information
Location
Region
North America
Country
Canada
City
Montreal
Corporate office
Montreal, Quebec, Canada
Additional offices
Halifax, Nova Scotia, Canada · Naperville, IL, United States · Lake Forest, CA, United States · Gosselies, Belgium · Antwerp, Belgium · Baulkham Hills, Australia · Jining, China
Sector focus
Frequently asked questions
What services does CellCarta offer?
CellCarta provides specialty laboratory services for drug development, including immunology, histopathology, proteomics, genomics, and digital pathology testing. These services support the entire drug development cycle from translational research to clinical trials (per CellCarta website).
Where are CellCarta's laboratory locations?
CellCarta operates laboratory and office facilities in Montreal and Halifax (Canada); Naperville, IL and Lake Forest, CA (United States); Gosselies and Antwerp (Belgium); Baulkham Hills (Australia); and Jining, China (per CellCarta website).
Who owns CellCarta?
CellCarta does not publicly disclose its ownership structure. The firm's website and public materials list no named principals, investors, or parent companies. It is privately held.
Does CellCarta disclose its financial data?
CellCarta does not disclose AUM, revenue, or deployment figures. The firm's website provides no financial information.
What types of clients does CellCarta serve?
CellCarta serves pharmaceutical and biotechnology companies conducting drug development programs. Its services are designed to support both translational research and clinical trials (per CellCarta website).
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: